Successful treatment of aortic arch mural thrombosis with low-dose, ultra-slow-flow thrombolysis: a case report and literature review

• Published in: Bleeding, Thrombosis and Vascular Biology Thrombosis and Vascular Biology, 2022-10, Vol.1 (3)
• Main Authors: Albisinni, Rosina, Marrazzo, Tommaso, Karruli, Arta, Manduca, Sabrina, Nobile, Giuseppe, Galdieri, Nicola, De Feo, Marisa
• Format: Article
• Language: English
• Subjects: alteplase; aortic arch; low-dose ultra-slow-flow; thrombolysis; thrombosis
• ISSN: 2785-5309; 2785-5309
• DOI: 10.4081/btvb.2022.44

Aortic arch thrombosis represents a severe condition which usually requires surgical treatment in specialized centers. Treatments described in literature are mostly surgery or sodium heparin infusion. Here we describe an off-label use of alteplase in aortic arch thrombosis in a patient in whom sodium heparin treatment failed and surgery was not possible due to the site of thrombus. We report the case of a 34-year-old postpartum patient who was admitted to our hospital for aortic arch thrombosis. She had no genetic disorders for hypercoagulability, only a family history for ischemic cerebrovascular accident. As treatment with sodium heparin failed and surgery was not possible due to the site of thrombus, she received a low-dose, ultra-slow-flow treatment with alteplase for 75 hours with successful removal of the thrombus. No side effects from alteplase were observed. Considering the safety and efficacy in this patient, as well as the easiness by which it can be reproduced in the majority of clinical settings, this treatment may be a viable option in cases of aortic arch thrombosis when conventional treatments are not applicable or available.